Chromatin Bioscience Signs Collaboration Agreement with Astellas
EDINBURGH, Scotland, April 14, 2025 /PRNewswire/ -- Chromatin Bioscience, a leader in the design of synthetic promoters and gene control systems, is pleased to announce a collaboration agreement with Astellas Pharma, a global life sciences company. Under the agreement, Chromatin Bioscience will use its proprietary chromatinLENS platform to design cell-selective synthetic promoters aligned...
PRISM BioLab and Elix Join Forces to Accelerate AI-Driven Drug Discovery for Protein-Protein Interaction Targets
Strategic Partnership Aims to Create Novel Drug Discovery Pipeline for Unmet Medical Needs by Combining PPI Control Technology with AI Drug Discovery Platform TOKYO, April 14, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM BioLab"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets,...
MGI Tech Celebrates 10 Years of DNBSEQ™ Technology: Driving Genomics Forward with Speed, Scale, and Accessibility
SHENZHEN, China, April 14, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, proudly marks a decade since the commercialization of its proprietary DNBSEQ™ sequencing technology. Over the past ten years, DNBSEQ™ has transformed the landscape of genomics...
CMEF Shanghai 2025 Wraps Up in Shanghai with Record-Breaking Innovations and Global Participation
SHANGHAI, April 14, 2025 /PRNewswire/ -- The 91st China International Medical Equipment Fair (CMEF) concluded on April 11, 2025, in Shanghai, after featuring groundbreaking medical technologies from nearly 5,000 exhibitors and attracting hundreds of thousands of attendees from more than 150 countries. CMEF has evolved into a premier international medical exhibition covering...
Fangzhou Presents AI-Driven Healthcare Ecosystem at Guangzhou Biotech Innovation Salon
GUANGZHOU, China, April 14, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leading Internet healthcare solution provider, participated in the "AI Empowers Biopharma" exchange panel hosted by the Guangzhou Development District Talent Education Group on April 3, 2025, joining 28 enterprises to explore cutting-edge applications of AI healthcare....
Over 3 million children died from AMR-related infections in 2022, major study shows
A landmark study presented today at ESCMID Global 2025 has revealed that over 3 million children worldwide lost their lives in 2022 due to antimicrobial resistance (AMR)-related infections. VIENNA, April 12, 2025 /PRNewswire/ -- The study underscores the urgent need for both regional and global strategies to control paediatric AMR, particularly in high-burden areas such as South-East Asia...
Clinical research results for Kelun-Biotech’s TROP2 ADC sacituzumab tirumotecan (sac-TMT) published in Nature Medicine, a top international medical journal
CHENGDU, China, April 12, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that results from a Phase 3 registrational clinical study evaluating the novel TROP2 antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) for the treatment of adult patients with advanced triple-negative breast cancer (TNBC) and results from an...
Patrick Tan appointed as Duke-NUS Dean to lead next era of medical innovation and education
SINGAPORE, April 11, 2025 /PRNewswire/ -- Duke-NUS Medical School has appointed Professor Patrick Tan as its next and fourth Dean, effective 1 January 2026, marking a new chapter for the School as it builds on its legacy of medical education, research and innovation. Prof Tan will serve as Dean-designate from 1 July 2025, succeeding Professor Thomas Coffman, the School's longest-serving...
Global First Engineered Exosome with INCI Name — ImmVira Leads a New Era in International Cosmetic Ingredients
SUZHOU, China, April 10, 2025 /PRNewswire/ -- EonveLab, a subsidiary of ImmVira Group ("ImmVira," or the "Company"), recently announced that its in-house developed engineered exosome product, MVR-EX103, developed for treating superficial skin depressions, has successfully passed the review of the International Cosmetic Ingredient Nomenclature Committee ("INC") and been officially granted a standardized International...
Health In Tech Announces Appointment of Sanjay Shrestha to Board of Directors
STUART, Fla., April 11, 2025 /PRNewswire/ -- Health In Tech (Nasdaq: HIT), an Insurtech platform company backed by third-party AI technology, is pleased to announce the appointment of a new independent director, Sanjay Shrestha, to the Company's Board of Directors (the "Board"). Mr. Shrestha will serve as a member of the Audit...
